{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-047678","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.290363+00:00","generated_at":"2026-05-24T01:53:58.844567+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cue Biopharma Q4 2024 net loss narrows to $9.5M; cash at $22.5M; pipeline pivots to autoimmune","bullets":["Net loss of $9.5M in Q4 2024 ($0.13/share) vs $13.4M in Q4 2023; full year net loss $40.7M.","Collaboration revenue $1.6M in Q4 vs $1.8M a year ago; full year rev $9.3M from Ono Pharma deal.","R&D spend cut to $7.2M (Q4) from $10.9M; cash and equivalents $22.5M as of Dec 31, 2024.","Regained worldwide rights to CUE-401 (autoimmune lead); prioritizing autoimmune over oncology.","Appointed Lucinda Warren (CBO), Dr. Daniel Baker (Interim CDO), Dr. Pasha Sarraf (Board)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-047678","json":"https://secwatch.observer/filing/0000950170-25-047678.json","markdown":"https://secwatch.observer/filing/0000950170-25-047678.md","text":"https://secwatch.observer/filing/0000950170-25-047678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000095017025047678/0000950170-25-047678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000095017025047678/cue-20250331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:53:58.844567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}